High-throughput imaging method for direct assessment of GM1 ganglioside levels in mammalian cells.

Walter Acosta, Reid Martin, David N Radin, Carole L Cramer

Open access · goldAbstract read

In one paragraph

Article in Data in brief, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

0.5field-weighted citation impact, top 29% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

Pre-diagnosing and managing patients with GM1 gangliosidosis and related disorders by the evaluation of GM1 ganglioside content.Scientific reports · 2019
Article
Case reports of juvenile GM1 gangliosidosisis type II caused by mutation in GLB1 gene.BMC medical genetics · 2017
Article
Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.Molecular genetics and metabolism · 2016
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Walter AcostaBioStrategies LC, State University, P.O. Box 2428, AR 72467, USA.

Reid MartinBioStrategies LC, State University, P.O. Box 2428, AR 72467, USA; Arkansas Biosciences Institute & Department Biological Sciences, Arkansas State University, P.O. Box 639, Jonesboro, AR 72467, USA.

David N RadinBioStrategies LC, State University, P.O. Box 2428, AR 72467, USA.

Carole L CramerBioStrategies LC, State University, P.O. Box 2428, AR 72467, USA; Arkansas Biosciences Institute & Department Biological Sciences, Arkansas State University, P.O. Box 639, Jonesboro, AR 72467, USA.

BioStrategies (United States) · USArkansas State University · US

Funding

Enzyme Replacement Therapy for GM1 Gangliosidosis Lysosomal Rare DiseaseR43NS084565 · NINDS · BIOSTRATEGIES, LC · PI CRAMER, CAROLE L., D'AZZO, ALESSANDRA · 2014 to 2014

$225k

NINDS NIH HHS R43 NS084565

6 · The paper itself

Abstract

GM1-gangliosidosis is an inherited autosomal recessive disorder caused by mutations in the gene GLB1, which encodes acid β-galactosidase (β-gal). The lack of activity in this lysosomal enzyme leads to accumulation of GM1 gangliosides (GM1) in cells. We have developed a high-content-imaging method to assess GM1 levels in fibroblasts that can be used to evaluate substrate reduction in treated GLB1(-/-) cells [1]. This assay allows fluorescent quantification in a multi-well system which generates unbiased and statistically significant data. Fluorescently labeled Cholera Toxin B subunit (CTXB), which specifically binds to GM1 gangliosides, was used to detect in situ GM1 levels in a fixed monolayer of fibroblasts. This sensitive, rapid, and inexpensive method facilitates in vitro drug screening in a format that allows a high number of replicates using low working volumes.

Indexed as

Acid β-galactosidaseCholera toxin B subunitGM1-gangliosidosisHigh-throughput imaging

Identifiers

PMID26958633

DOI10.1016/j.dib.2016.01.027

PMCPMC4763105

OpenAlexW2269757135

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.